Waiting for the next wave...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I created a graph of the cns sales LCI had since September 2018
It went down from sep 2018 q to dec 2018 q by 50% 14.2mil to 7.3 mil
Then they went up from 7.3 mil to 21 mil in 2 quarters (June 2019) then down 3 quarters in a row to March 2020 (18.5 mil) then up 3 quarters in a row to 24.6 mil.
The decline from June 2019 to March 2020q shows that it was LCI cns drugs that are going down because elite revenues went up steadily.
And since March 2020 q sales are going up steadily. (Aderal er)
The launch was on March 31st. Profit split is from sold units. So they fall after clients sell them.
Starts after 6 months.
Not from adderall er. It should be the first time.
This quarter we should get some profit split if I am not wrong.
$8,200,000 is my prediction.
Profit 3,000,000
Great analysis. Thank you
We have established there is growth. This is what is important.
Faster growth will come when Covid is over.
But lannett is delivering.
We need the answer to the question Nasrat asked last time
What are we going to do with the money?
A hint we got on Jan 5 was investing in R&d.
SUCCESSFUL LAUNCH !!!
No - I do not agree...
only 3% decline compared to last quarter. It is in the 2 last LCI Sec filings.
namtae - Great news...
I looked at the previous 10-Q from LCI - and last quarter the price drop compARED TO 2019 WAS 43% AND SALES INCREASE 60%
sO THE INCREMENTAL DROP WAS 3% FOR PRICE AND 13% FOR VOLUME...
from LCI 10-Q:
Gross Profit. Gross profit for the second quarter of Fiscal 2021 decreased 98% to $0.8 million or 1% of net sales. In
comparison, gross profit for the second quarter of Fiscal 2020 was $41.3 million or 30% of net sales. The decrease in gross
profit percentage was primarily attributable to lower volumes of Fluphenazine, which had higher than average gross profit
margins, as well as overall lower average selling prices of our products. The Company also recorded an increase in the
write-downs for excess and obsolete inventory as well as consideration to renew the distribution agreement with Recro in
the second quarter of Fiscal 2021.
The only impact to Elite is in profit split - but way compensated by the number of units sold...
namtae - Manufacturing fees are constant - they must be in the contract with Lannett.
The proof is in the Sec Pudding
namtae:
Look at LCI profitability - it has been hit big time.
775K versus 25 Million last quarter... lol
and the cherry on top of the Pudding on page 41:
The decrease in sales to retail chains was primarily driven by lower sales of Fluphenazine due to a new competitor entering
the market.
namtae - think...
it takes $1 to make this pound of orange.
The supply chain will take a hit if the price goes down.
I will charge the same price when I sell the orange to the supply chain...
73% growth !!!!!
namtae - I would beg to differ with you.
The cost to make a product is constant - what is being hit is the profit margin.
So do not expect to have the manufacturing cost go down by 46% - Manufacturing cost is constant - up by 73% lol
The Million dollar question is:
Is the manufacturing cost (which is the main revenue stream of Elite) fix or variable based on the price of the drug...
In other words - by selling 73% more Adderall at 46% less price - are we making more money in manufacturing and taking less in profit split?
It is amazing how each person looks at the same information differently:
I was looking at the 73% More sales
namtae was looking at the 46% price decrease lol:
WOW!! Wonder if investors skipped over this very important bit of information
Quote:
price is going down by 46%
This may have huge ramifications for Elites earning report
Page 40 of the new LCI 10-Q Sec filing shows that there is a huge growth in sales of Units (73%) for CNS drugs but there is a lot of competition so the price is going down by 46%
This means that Elite is growing in terms of market share for CNS products - but it does not show in the revenues because they are selling cheaper.
BUT:
Elite has shown it could afford that by becoming more efficient - their Gross profit was 34% last year and 49% las quarter - so they are not hit as bad as if they had not implemented their SAP system.
I would add and manipulated...
JustGoDeep Member Level Thursday, 02/04/21 03:26:18 PM
Re: Je3232 post# 350348 0
Post #
350350
of 350354
Hmm, Is This Undervalued Stock Up 40%
For Openers!!
From $.05 to $.07
whoever brought it back tp $0.07 - thank you...
we need $0.030 for a decimal upgrade - and $.3 to make JE3232 happy
40k shares away from $0.071
WHo thinks we can finish Green today?
Seriously this time - Lannett cut in less profitable drugs - they used the 80/20 rule.
Could well be that IR was dropped and what we see is just ER.
In that case, IR could be given to another partner.
No - it will be $0.06
They will cancel the Green trades - to make you happy
I am so surprised about your assessment...
Nasrat is a strategist - he will not spend his energy on each fluctuation of the stock price.
How $2 million net growth in sales of CNS products by Lannett impact the PPS...
I am speechless...
LANNETT COMPANY, INC.
NET SALES BY MEDICAL INDICATION
Three months ended Six months ended
($ in thousands) December 31, December 31,
Medical Indication 2020 2019 2020 2019
Central Nervous System 24,614 19,331 47,139 38,588
Lannett sold $2 Million more worth of CNS drugs last quarter compared to 2 quarters ago.
LANNETT COMPANY, INC.
NET SALES BY MEDICAL INDICATION
Three months ended Six months ended
($ in thousands)
December 31, December 31,
Medical Indication 2020 2019 2020 2019
Central Nervous System 24,614 19,331 47,139 38,588
So the sales of CNS went up by 2.089 Million last quarter.
We should expect a bump in Elite's revenues.
Realistic Value for a company is subjective and hard to have an agreement on it.
When you see a company with P/E ratio of 800 or valuations for Tesla or Amazon, or Microsoft or even Teva, it is hard to comprehend how a company can be evaluated so high.
We are in a P/E ratio of 15-25 - and it is subjective - being profitable, we could be at a P/E ratio of 80.
Some say we should have a P/E ratio of 5... this is their view and we need to respect it - but no one is right or wrong...
I agree that if we had a Branded pipeline, we would have a higher P/E ratio because we would be protected for a patent for a number of years.
Being in the Generics, we are less protected and being profitable shows a great management
My view....
To be truthful I can wait another 5 years to get to $$ land - but I would appreciate it earlier.
Dime is achievable today !!!
Look at Level II - totally doable.
I think what new investors have hard time understanding is that this company is its infancy with a Market Capitalization of less than $1 Million and 330000 outstanding shares.
This means that when the revenues of the company are reported, it will be profitable day 1.
It will go up like a NASA capsule to the moon...
I appreciate it !!!
After sending an email today to Elite about the Pipeline on their website, they made a big change on the site today.
It says now under Generic Pipeline:
GENERIC PIPELINE
Elite is developing differentiated niche generic products for future growth. Elite’s focus is on solid oral dose products that are hard to formulate, such as extended-release products and products that we believe have competitive advantages. Elite also continues to evaluate contract development, contract manufacturing, and in-licensing opportunities. Updates on development projects will be provided upon achieving key milestones.
They did clean up a lot... lol
sooo close to $0.07...
Please keep the cheering to yourself - this is a breakdown room - people notice only the movements downwards...
This said, I agree with you.
Sorry it is the Gazprom report
We have the results of the Energir tests filed at the SEC.
This is serious guys:
https://sec.report/otc/financial-report/269858